The Therapeutic Synergy of EMS DolorClast® High-Power Laser and Shockwave Therapy in Musculoskeletal Medicine

The evolution of non-invasive musculoskeletal care has increasingly shifted toward biologically targeted interventions that address both the underlying drivers of pathology and the mechanical deficits that perpetuate dysfunction. Among these, extracorporeal shock wave therapy (ESWT) and photobiomodulation (PBM) using pulsed 905 nm laser technology represent two of the most extensively investigated and clinically effective modalities.

While each therapy demonstrates independent efficacy across a wide range of musculoskeletal conditions, emerging evidence and mechanistic insights suggest that their combined application produces a synergistic effect, enhancing clinical outcomes beyond what either modality can achieve in isolation. This synergy is particularly relevant in conditions characterised by neurogenic inflammation, failed tissue healing, and persistent nociceptive sensitisation, such as tendinopathies, myofascial pain syndromes, and chronic overuse injuries.

At Movement Mechanics Osteopathy, the integration of EMS DolorClast® Radial and Focused Shockwave Therapy with EMS DolorClast® High-Power Laser (905 nm) reflects a commitment to delivering precision-guided, evidence-based care grounded in contemporary musculoskeletal science.

Understanding the Pathophysiological Target — Neurogenic Inflammation and Failed Healing

A critical paradigm shift in musculoskeletal medicine has been the recognition that many chronic conditions traditionally described as “degenerative” are, in fact, driven by persistent neurogenic inflammation. This process is mediated by neuropeptides such as substance P and calcitonin gene-related peptide (CGRP), alongside pro-inflammatory cytokines including interleukin-1β and tumour necrosis factor-alpha (TNF-α).

These mediators not only contribute to pain generation but also actively impair tissue regeneration. Experimental work has demonstrated that exposure of tendon-derived cells to inflammatory cytokines inhibits the expression of scleraxis, a transcription factor essential for tendon differentiation and collagen synthesis  . Without the re-establishment of this molecular environment, effective tissue healing cannot occur.

Furthermore, neurogenic inflammation amplifies nociceptive signalling through peripheral sensitisation. Prostaglandins derived from arachidonic acid increase the excitability of peripheral nociceptors, resulting in heightened pain perception and sustained dysfunction (Jang et al., 2020). This creates a self-perpetuating cycle in which inflammation drives pain, and pain inhibits appropriate loading and rehabilitation.

From a clinical perspective, this reinforces a key principle:

successful treatment requires both resolution of neurogenic inflammation and stimulation of regenerative processes.

Mechanistic Foundations of EMS DolorClast® High-Power Laser Therapy (905 nm)

Photobiomodulation therapy using pulsed 905 nm laser operates within the near-infrared therapeutic window, allowing deep tissue penetration with minimal attenuation. The defining characteristic of EMS DolorClast® High-Power Laser technology is its high peak power output delivered in ultra-short pulses, enabling substantial biological stimulation without excessive thermal load.

At a cellular level, PBM influences mitochondrial function, particularly through modulation of cytochrome c oxidase, resulting in increased ATP production and enhanced cellular metabolism. In addition to these metabolic effects, PBM exerts significant influence on inflammatory pathways.

Randomised controlled evidence has demonstrated that low-level laser therapy at wavelengths around 904–905 nm can significantly reduce prostaglandin E2 concentrations in tendinopathic tissue, correlating with measurable reductions in pain and inflammation (Bjordal et al., 2006)  . Importantly, prostaglandins are key mediators of nociceptor sensitisation, meaning their reduction directly impacts pain perception.

Further mechanistic studies indicate that pulsed laser delivery produces effects beyond classical photochemical interactions. The combination of high peak power and low duty cycle may induce transient changes in cellular membrane permeability and intracellular signalling pathways, potentially through selective photothermal and photomechanical effects (Moriyama et al., 2009)  .

Clinically, this manifests as:

• Rapid analgesia through reduced nociceptor firing

• Modulation of inflammatory mediators

• Improved cellular readiness for tissue repair

Mechanistic Foundations of EMS DolorClast® Shockwave Therapy

Extracorporeal shock wave therapy is one of the most robustly supported modalities in musculoskeletal medicine, with over 100 randomised controlled trials demonstrating its safety and efficacy across a range of orthopaedic conditions (Schmitz et al., 2015)  .

Shockwaves are characterised by high-pressure acoustic impulses that generate rapid mechanical stress within tissues. This mechanical stimulus initiates a cascade of biological responses collectively referred to as mechanotransduction.

These responses include increased expression of growth factors, stimulation of fibroblast activity, and enhanced collagen synthesis. In tendon tissue, this promotes structural remodelling and restoration of functional integrity. Additionally, shockwave therapy induces neovascularisation, improving local blood supply and facilitating nutrient delivery to previously compromised tissues.

Another critical mechanism involves the modulation of pain-related neuropeptides. Shockwave application has been shown to influence the release and subsequent reduction of substance P, which is closely linked to the temporal pattern of pain experienced following treatment  . This aligns with the clinical observation of initial discomfort followed by sustained pain relief.

From a functional perspective, these mechanisms translate into meaningful clinical outcomes. In elite athletic populations, the addition of radial shockwave therapy to rehabilitation programmes has been associated with substantial reductions in return-to-play time, in some cases exceeding 50% compared to historical controls.

The Biological Basis for Synergy — Why Combination Therapy Outperforms Monotherapy

The rationale for combining EMS DolorClast® High-Power Laser and Shockwave Therapy lies in their complementary effects on different stages of the pathological process.

Laser therapy primarily addresses the biochemical and neurophysiological environment, reducing inflammation and nociceptive sensitisation. In doing so, it effectively “primes” the tissue, creating conditions more conducive to regeneration.

Shockwave therapy, in contrast, provides a mechanical stimulus that drives structural adaptation and tissue repair. However, its effectiveness is influenced by both patient tolerance and the underlying inflammatory state of the tissue.

By applying laser therapy prior to shockwave treatment, clinicians can reduce pain sensitivity and improve patient comfort, allowing for the application of higher energy flux densities, which are known to enhance therapeutic outcomes. This concept is supported by evidence indicating that insufficient energy delivery negatively impacts ESWT efficacy, while higher tolerated doses produce superior results  .

Furthermore, resolving neurogenic inflammation prior to mechanical stimulation aligns with fundamental biological principles of tissue healing. As highlighted in experimental models, tendon regeneration requires an environment in which inflammatory cytokines are controlled and cellular differentiation pathways can proceed normally  .

The combined approach therefore achieves a sequential therapeutic effect:

1. Modulation of inflammation and nociception (laser)

2. Induction of regeneration and structural adaptation (shockwave)

This represents a more comprehensive intervention targeting the full spectrum of musculoskeletal pathology.

Clinical Evidence Supporting Combination Therapy

Clinical research investigating the combination of photobiomodulation and shockwave therapy has demonstrated superior outcomes compared to either modality alone. Randomised controlled trials examining conditions such as plantar fasciopathy have shown that combination therapy results in greater reductions in pain scores, improved functional outcomes, and sustained benefits over time.

These findings are consistent with broader literature demonstrating that multimodal approaches are often more effective in complex musculoskeletal conditions, particularly where both inflammatory and mechanical components are present.

Importantly, the effectiveness of shockwave therapy itself has been further validated when combined with structured rehabilitation. For example, studies have shown that ESWT combined with loading programmes produces better outcomes than loading alone, reinforcing the concept that mechanical and biological interventions should not be considered in isolation.

Optimising Treatment Delivery — Timing, Dosage, and Clinical Decision-Making

The integration of laser and shockwave therapy requires thoughtful clinical reasoning. A key consideration is whether neurogenic inflammation is a dominant feature of the patient’s presentation. Where this is the case, prioritising laser therapy as an initial intervention can significantly enhance subsequent treatment response.

Clinical protocols derived from GDT principles suggest that short-duration laser application prior to shockwave therapy is sufficient to achieve meaningful biological effects. Depending on the desired outcome, a brief interval between modalities may be employed, allowing for optimal tissue response before mechanical stimulation is introduced  .

The concept of tailoring treatment based on desired outcomes, ranging from “good” to “optimal” reflects an advanced, patient-centred approach that considers both biological and functional goals.

The Importance of Device Quality — Why EMS DolorClast® Matters

The effectiveness of both laser and shockwave therapy is highly dependent on the quality and consistency of energy delivery. Variability in device output, particularly with respect to energy flux density and frequency, can significantly influence clinical outcomes.

Research comparing different shockwave devices has demonstrated that energy stability across frequencies varies between systems, underscoring the importance of using clinically validated technology  . EMS DolorClast® systems are designed to deliver consistent, reproducible energy, ensuring that treatment parameters align with those used in high-quality clinical studies.

Similarly, the high peak power and pulsed delivery characteristics of EMS DolorClast® laser technology distinguish it from lower-powered or continuous-wave systems, enabling deeper and more effective tissue interaction.

Clinical Implications for Patients on Auckland’s North Shore

For patients experiencing persistent pain, recurrent injury, or slow recovery, the integration of EMS DolorClast® Laser and Shockwave Therapy offers a highly effective, non-invasive alternative to more aggressive interventions.

By addressing both the inflammatory and structural components of musculoskeletal pathology, this combined approach can:

• Accelerate recovery timelines

• Reduce reliance on medication or injections

• Improve long-term functional outcomes

At Movement Mechanics Osteopathy, this is delivered within a broader framework that includes osteopathy, rehabilitation, and advanced movement analysis, ensuring that treatment extends beyond symptom relief to address underlying dysfunction.

A New Standard in Evidence-Based Musculoskeletal Care

The combination of EMS DolorClast® High-Power Laser Therapy and Shockwave Therapy represents a clinically and biologically coherent approach to musculoskeletal treatment. By integrating modulation of neurogenic inflammation with stimulation of tissue regeneration, this strategy aligns with contemporary understanding of pain and healing.

As the evidence base continues to evolve, it is increasingly clear that multimodal, mechanism-driven interventions will define the future of musculoskeletal medicine. The synergy between laser and shockwave therapy exemplifies this shift, offering clinicians a powerful tool to achieve superior outcomes in complex and chronic conditions.

Frequently Asked Questions (FAQs)

What is the benefit of combining shockwave therapy and laser therapy?

Combining shockwave therapy with high-power laser therapy allows clinicians to address both the biological and mechanical drivers of musculoskeletal pain. Laser therapy (photobiomodulation) reduces neurogenic inflammation and sensitisation of pain pathways, while shockwave therapy stimulates tissue regeneration through mechanotransduction. When used together, this approach enhances treatment tolerance, allows higher therapeutic dosing, and leads to improved outcomes in conditions such as tendinopathy, plantar fasciitis, and shoulder pain.

Is EMS DolorClast® laser therapy better than standard laser therapy?

EMS DolorClast® High-Power Laser uses a pulsed 905 nm wavelength with high peak power, which enables deeper tissue penetration and stronger biological effects compared to many continuous-wave or low-power laser systems. This allows for more effective modulation of inflammation, improved pain reduction, and enhanced preparation of tissues prior to shockwave therapy. Device quality and energy delivery consistency are critical factors in clinical outcomes.

Why is 905 nm laser used for musculoskeletal conditions?

The 905 nm wavelength sits within the near-infrared therapeutic window, allowing optimal penetration into deeper musculoskeletal tissues such as tendons, muscles, and joints. Research demonstrates that this wavelength can reduce inflammatory mediators, improve mitochondrial activity, and decrease nociceptor sensitivity, making it particularly effective for treating chronic pain and soft tissue injuries.

Does combining laser and shockwave therapy speed up recovery?

Yes, combining these therapies can accelerate recovery by addressing multiple stages of the healing process. Laser therapy reduces inflammation and pain early in treatment, allowing patients to tolerate higher energy levels during shockwave therapy. Shockwave therapy then stimulates tissue repair and regeneration. Clinical evidence suggests this combined approach can improve function, reduce pain more quickly, and shorten recovery timelines compared to single-modality treatment.

What conditions benefit most from shockwave and laser therapy combined?

The combination is particularly effective for conditions involving chronic inflammation and failed healing responses. These include Achilles tendinopathy, plantar fasciitis, lateral epicondylalgia (tennis elbow), rotator cuff tendinopathy, patellar tendinopathy, and chronic muscle injuries. It is also beneficial in post-surgical rehabilitation where tissue healing needs to be optimised.

Is shockwave therapy or laser therapy better for pain relief?

Both therapies are effective for pain relief but work through different mechanisms. Laser therapy provides rapid analgesia by reducing nociceptor activity and inflammatory mediators, while shockwave therapy produces longer-term pain reduction by addressing underlying tissue dysfunction. When combined, patients typically experience both immediate relief and sustained improvement.

How many sessions of combined shockwave and laser therapy are needed?

Most treatment plans involve a course of 3–6 sessions, typically spaced one week apart for shockwave therapy, with laser therapy applied within each session. The exact number depends on the condition, severity, and individual response to treatment. Evidence suggests that consistent, appropriately dosed sessions are key to achieving optimal outcomes.

Is EMS DolorClast® shockwave therapy the best option in Auckland?

EMS DolorClast® systems are among the most clinically researched and widely used shockwave devices globally, with strong evidence supporting their effectiveness and safety. Their ability to deliver consistent energy output and integrate both radial and focused shockwave technologies makes them a premium option for musculoskeletal care in Auckland and the North Shore.

Does shockwave therapy break down tissue or damage it?

No, shockwave therapy does not damage healthy tissue. Instead, it creates controlled mechanical stimulation that promotes healing. This includes increased blood flow, collagen production, and cellular activity. The goal is not to break tissue down, but to stimulate a regenerative response in areas where healing has stalled.

Is the combination of laser and shockwave therapy safe?

Yes, when performed by a trained clinician, the combination is safe and well tolerated. Both modalities are non-invasive and have strong safety profiles supported by clinical research. Appropriate screening is required to rule out contraindications such as malignancy, active infection, or certain vascular conditions.

Where can I get shockwave and laser therapy on the North Shore, Auckland?

Movement Mechanics Osteopathy offers EMS DolorClast® Shockwave Therapy and High-Power Laser Therapy at our purpose-built clinic in Browns Bay (13–15 Bute Road). We provide same-week appointments, ACC support, and integrated treatment plans designed to get you moving better, faster.

---

Jonathan Hall M.Ost, BAppSci (Human Biology), PGCertHSc (Acupuncture), GradDipHeal

Jonathan Hall is the founder and principal Osteopath at Movement Mechanics Osteopathy.  Jonathan specialises in Shockwave Therapy and Western medical acupuncture and a Key opinion leader for EMS Swiss DolorClast. A fully qualified Osteopath registered with OCNZ, PNZ, PAANZ and ACC, Jonathan also founded Auckland Shockwave Therapy to help bring evidence-based Shockwave treatment to New Zealand using the industry-leading EMS Radial Shock Wave device.

Book an appointment with Jonathan here.

Contact Us: hello@movementmechanics.nz

References

Bjordal, J. M., Lopes-Martins, R. Á. B., & Iversen, V. V. (2006). A randomized placebo-controlled trial of low-level laser therapy for activated Achilles tendinitis. British Journal of Sports Medicine, 40(1), 76–80.

Jang, Y., Kim, M., & Hwang, S. W. (2020). Molecular mechanisms underlying prostaglandins in peripheral nociception. Journal of Neuroinflammation, 17(1), 30.

Moriyama, Y., Nguyen, J., Akens, M., Moriyama, E. H., & Lilge, L. (2009). In vivo effects of low-level laser therapy on inducible nitric oxide synthase. Lasers in Surgery and Medicine, 41(3), 227–231.

Schmitz, C., Császár, N. B. M., Milz, S., Schieker, M., Maffulli, N., Rompe, J. D., & Furia, J. P. (2015). Efficacy and safety of extracorporeal shock wave therapy for orthopedic conditions. British Medical Bulletin, 116, 115–138.

Morgan, J., Hamm, M., Schmitz, C., & Brem, M. (2021). Return to play after treating acute muscle injuries with radial ESWT. Journal of Orthopaedic Surgery and Research, 16(1), 708. 

Rompe, J. D., Furia, J. P., & Maffulli, N. (2009). Eccentric loading versus eccentric loading plus shockwave therapy. American Journal of Sports Medicine, 37(3), 463–470. 

Zhang, Y. F., Liu, Y., Chou, S. W., & Weng, H. (2021). Dose-related effects of radial shockwave therapy for knee osteoarthritis. Journal of Rehabilitation Medicine, 53, jrm00144. 

Additional supporting material sourced from GDT Summit Australia presentation

Disclaimer: This content is for educational purposes and is not a substitute for professional medical advice.

© Movement Mechanics Osteopathy Auckland 2024. All rights reserved.